Strata Skin Sciences provides update on positioning, litigation

STRATA Skin Sciences (SSKN) provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek, and affiliated entities including The Pinnacle Health Group and C. Dalton International. As previously disclosed, on November 8, 2024, the U.S. District Court for the Eastern District of Pennsylvania issued an order partially granting STRATA’s motion for preliminary injunction. In a subsequent decision, the Court also agreed with STRATA’s position that LaserOptek Korea should be added as a defendant, citing efforts by the defendants to obscure their involvement. Over the past few months, STRATA has successfully engaged multiple dermatology clinics that were previously misled by false claims about the Pallas solid-state laser’s capabilities and reimbursement eligibility. To date, over 20 such LaserOptek Pallas buyers have partnered with STRATA on XTRAC excimer laser technology under XTRAC partnership program or purchased XTRAC excimer lasers. These accounts represent over $1 million in annualized capital and recurring revenue. There are currently around 1,200 U.S. dermatology clinics that use excimer laser therapy for the treatment and subsequent ethical insurance billing of dermatologic autoimmune conditions such as psoriasis and vitiligo subject to CPT codes 96920 – 96922. All of these clinics are using either the XTRAC or Pharos devices – both are STRATA products. As of June 30, 2025, 844 of these clinics are using excimer laser technology under STRATA’s partnership program.